4//SEC Filing
Cohen Joshua B 4
Accession 0001193125-26-017057
CIK 0001658551other
Filed
Jan 19, 7:00 PM ET
Accepted
Jan 20, 9:46 PM ET
Size
13.7 KB
Accession
0001193125-26-017057
Insider Transaction Report
Form 4
Cohen Joshua B
DirectorCo-Chief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2026-01-15$7.57/sh+197,182$1,492,668→ 3,514,814 total - Sale
Common Stock
[F1][F2]2026-01-15$13.59/sh−136,193$1,850,795→ 3,378,621 total - Exercise/Conversion
Common Stock
2026-01-16$7.57/sh+2,818$21,332→ 3,381,439 total - Sale
Common Stock
[F1][F3]2026-01-16$13.83/sh−1,974$27,299→ 3,379,465 total - Exercise/Conversion
Stock Option (Right to Buy)
[F4]2026-01-15−197,182→ 2,818 totalExercise: $7.57Exp: 2026-02-19→ Common Stock (197,182 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F4]2026-01-16−2,818→ 0 totalExercise: $7.57Exp: 2026-02-19→ Common Stock (2,818 underlying)
Footnotes (4)
- [F1]Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.26 to $13.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.82 to $13.835. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]This option is fully vested and exercisable. The option is due to expire on February 19, 2026.
Signature
/s/ Joshua B. Cohen|2026-01-20
Documents
Issuer
Amylyx Pharmaceuticals, Inc.
CIK 0001658551
Entity typeother
Related Parties
1- filerCIK 0001898644
Filing Metadata
- Form type
- 4
- Filed
- Jan 19, 7:00 PM ET
- Accepted
- Jan 20, 9:46 PM ET
- Size
- 13.7 KB